-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

Sponsor: Sanofi. Provided by Clinical Care Options, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies
Friday, December 8, 2023: 3:00 PM-6:00 PM
San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Catherine Broome, MD, Georgetown University
Broome: Argenx; Incyte; Rigel; Sanofi; Star Therapeutics: Research Funding; Alexion; Dianthus: Consultancy.
David Dingli, MD, Mayo Clinic and Deva Sharma, MD, Vanderbilt University School of Medicine
Dingli: BMS: Consultancy; Apellis: Consultancy; Janssen: Consultancy; K-36 Therapeutics: Research Funding; Novartis: Consultancy; Sanofi: Consultancy; Sorrento: Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Alexion (AstraZeneca); Apellis Pharmaceuticals; BMS; GSK; Janssen; Novartis; Sanofi; Takeda: Consultancy; BioCryst: Consultancy.
This interactive symposium will feature a unique learning opportunity to gain and update on the latest clinical advances in the care of patients with cold agglutinin disease (CAD). The symposium format will include presentations and case-based panel discussions with perspectives and treatment recommendations from multiple experts. In addition, the panel will address audience questions and practice challenges identified in the “Live Case and Question Submission”, which can be sent directly to the symposium faculty. You can expect to receive a review of cutting-edge clinical evidence along with a presentation of evolving treatment algorithms for CAD into 2024. Program topics will include an overview CAD and the associated pathophysiology, clinical presentation and diagnosis of CAD; current/evolving management algorithm for the patient with newly diagnosed CAD and the management of CAD-related anemia, fatigue, and hemoglobinuria; challenges and strategies to address quality of life in patients with CAD; plus novel treatments on the horizon and future directions.